04/06/2019 - 10:54

PharmAust starts tablet production for Phase 2 cancer trials

04/06/2019 - 10:54


Upgrade your subscription to use this feature.

PharmAust has given US-based manufacturer Catalent the green light to start producing more Good Manufacturing Practice-grade Monepantel tablets for its upcoming Phase 2 anti-cancer clinical trials in dogs. The company plans to start recruiting dogs with B cell lymphoma in August or September this year for the Phase 2 trials, which will initially follow a 28-day treatment regimen.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options